Co-Authors
This is a "connection" page, showing publications co-authored by MEGHANA TRIVEDI and SUSAN ABUGHOSH.
Connection Strength
2.054
-
Group-Based Trajectory Model to Assess Adjuvant Endocrine Therapy Adherence Pattern in HR-Positive Breast Cancer: Results from Rio Grande Valley Patients. Healthcare (Basel). 2025 Jul 22; 13(15).
Score: 0.246
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
Score: 0.242
-
Group-Based Trajectory Modeling to Identify Patterns and Predictors of Adherence to Oral Endocrine Therapies in Underserved Population of Greater Houston Area. Patient Prefer Adherence. 2025; 19:473-484.
Score: 0.239
-
Immunomodulator adherence in multiple myeloma patients with lower socioeconomic status: a retrospective study. Support Care Cancer. 2024 Jun 04; 32(7):407.
Score: 0.227
-
Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic. Int J Clin Pharm. 2023 Dec; 45(6):1396-1404.
Score: 0.213
-
Identifying the predictors of adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status. Res Sq. 2022 Dec 22.
Score: 0.206
-
Oral Endocrine Therapy Agent, Race/Ethnicity, and Time on Therapy Predict Adherence in Breast Cancer Patients in a Large Academic Institution. Clin Breast Cancer. 2020 12; 20(6):520-526.
Score: 0.173
-
Neratinib in HER2-Positive Breast Cancer Patients. Ann Pharmacother. 2019 06; 53(6):612-620.
Score: 0.156
-
Identifying adherence barriers to oral endocrine therapy among breast cancer survivors. Breast Cancer Res Treat. 2019 Apr; 174(2):297-305.
Score: 0.155
-
Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence? J Cancer Surviv. 2018 06; 12(3):348-356.
Score: 0.147
-
Dose-dependent relation between metformin and the risk of hormone receptor-positive, her2-negative breast cancer among postmenopausal women with type-2 diabetes. Breast Cancer Res Treat. 2022 Oct; 195(3):421-430.
Score: 0.050